Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority trial of 1-month daily rifapentine + isoniazid (1HP) vs 3-month weekly rifapentine + isoniazid (3HP) for latent tuberculosis infection in non-HIV adults
TCTR20260210006Phase 4Not yet recruiting
- Sponsor
- Pluak Daeng Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifapentine, isoniazid in latent tuberculosis infection (LTBI), sponsored by Pluak Daeng Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on TCTR20260210006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260210006.